Avaxia Biologics awarded phase I SBIR grant to develop antibody therapeutic for oral mucositis

Source: www.reuters.com Author: press release Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for disease targets accessible via the GI tract, announced today that it has been awarded a Phase I SBIR grant from the National Institute of Dental and Craniofacial Research to support the development of a novel antibody therapeutic for oral mucositis. Avaxia is developing [...]